🟢 Neurosense Therapeutics is trading 7% up in pre-market with no clear catalyst identified

Neurosense Therapeutics is trading 7.04% up at $0.45, with no fresh company-specific announcement for August 31, 2026 identified.

• It reached $0.42 at the August 28 close.
• Recent coverage concerns earlier PrimeC regulatory progress, a planned December 2026 Health Canada filing, and reverse-split authorization discussions; none directly explains the pre-market move.
• The broader market is modestly lower, and confidence remains low pending a new filing or announcement.